Wave Life Sciences

Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Wave Life Sciences reports transformative 2022 with promising clinical advancements

Wave Life Sciences showcased strong clinical progress and financial discipline in Q4 2022.
The collaboration with GSK and advancements in RNA editing and RNAi technologies position Wave for future success.
Despite challenges in increased expenses, Wave's focus on innovative therapies and strategic partnerships bode well for their future.

Wave Life Sciences reports Q1 progress, poised for RNA innovation

Wave Life Sciences showcased strong financial performance, significant program advancements, and a leadership position in RNA editing technology during Q1 2023.
The company's strategic shift, collaboration with GSK, and focus on additional endpoints beyond traditional measures highlight their commitment to innovation and patient outcomes.
While facing challenges in study designs and editing efficiency assessments, Wave's opportunities lie in differentiation, partnerships, and further advancements in precision medicine.

Wave Life Sciences advances RNA editing technology and secures key collaborations

Wave Life Sciences showcased strong progress in RNA editing and clinical programs, bolstered by collaborations and financial stability.
While facing challenges in off-target effects and patient selection, Wave aims to demonstrate leadership in protein restoration through RNA editing.
Anticipated milestones from GSK, advancements in AIMer technology, and upcoming trial data offer promising opportunities for Wave's growth.

Wave Life Sciences reports strong Q3 earnings and advances RNA pipeline

Wave Life Sciences demonstrated financial strength with positive net income and a healthy cash position.
The company's focus on RNA medicine pipeline advancement and collaborations with GSK show promise for future growth.
Challenges lie in addressing questions on program development, treatment functionality, and ensuring treatment efficacy and patient compliance.

Wave Life Sciences reports successful 2023, eyes growth in RNA editing and obesity programs

Wave Life Sciences had a successful year in 2023, with promising advancements in key programs and a stable financial position.
The company faces challenges in managing expenses and meeting high expectations for upcoming clinical data readouts.
However, Wave's strengths lie in its innovative RNA editing technology, diversified pipeline, and collaborations for revenue generation.
Opportunities abound in market differentiation, revenue growth, and addressing unmet medical needs through their unique programs.

Wave Life Sciences reports Q1 loss but shows promise in therapies

Wave Life Sciences is making strides in advancing their therapeutic portfolio with promising clinical trial progress and positive preclinical results.
While facing challenges in program validation and expansion, the company's strong R&D efforts and financial stability position them well for future growth.
With upcoming milestones and a focus on innovative therapies, Wave has opportunities to establish itself as a key player in the biopharmaceutical industry.

Wave Life Sciences reports breakthroughs in RNA editing and clinical progress

Wave Life Sciences showcased a successful quarter with advancements in RNA editing and positive clinical trial outcomes, positioning the company for future growth.
While facing financial challenges, the company's strong cash position and promising pipeline present opportunities for sustained innovation and market expansion.
Navigating regulatory pathways for accelerated approvals and leveraging breakthrough technologies underscore Wave's potential for long-term success in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences Ltd's (NASDAQ: WVE) FOCUS-C9 study of WVE-004 shows reductions of poly(GP) dipeptide repeat proteins in cerebrospinal fluid (CSF) with low, single doses of WVE-004.  The Phase 1b/2a trial is assessing WVE-004 in C9orf72-associated amyotrophic lateral.

Wave Life Sciences Jump As Low Doses of WVE-004 Lowers Disease Biomarker In Neurological Indications

Reductions in poly(GP), a key disease biomarker indicating target engagement, observed across all treatment groups after single doses

Wave Life Sciences Announces Positive Update to Ongoing Phase 1b/2a FOCUS-C9 Study Driven by Potent, Durable Reductions of Poly(GP) with Low, Single Doses of WVE-004

CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate virtually in an analyst-led fireside chat at the Stifel 2022 CNS Days event on Monday, March 28, 2022, at 9:15 a.m. EDT.

Wave Life Sciences to Present at Stifel 2022 CNS Days

Presentation at OPT 2022 to highlight AATD program, including reduction of liver aggregates with repeat AIMer dosing out to 19 weeks

Wave Life Sciences to Highlight RNA Base Editing Modality and Alpha-1 Antitrypsin Deficiency Program at Upcoming Scientific and Industry Meetings

Published data demonstrate potent, durable, and specific editing and potential for therapeutic applications in liver using a subcutaneous GalNAc-conjugated oligonucleotide approach

Wave Life Sciences Announces Nature Biotechnology Publication Highlighting First RNA Base Editing in Non-Human Primates Using an Endogenous Enzyme

Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q4 2021 Results - Earnings Call Transcript

Clinical data from multiple novel, PN-modified stereopure oligonucleotides for ALS/FTD, DMD, and HD expected in 2022

Wave Life Sciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Thursday, March 3, 2022, to discuss its fourth quarter and full year 2021 financial results and provide a business update.

Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2021 Financial Results on March 3, 2022

CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Virtual 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 10:40 a.m. ET.

Wave Life Sciences to Present at the Virtual 11th Annual SVB Leerink Global Healthcare Conference 2022

Wave paper on PN chemistry for silencing in the CNS, and the implications for oligonucleotides more broadly, designated as a Breakthrough Article by Nucleic Acids Research

Wave Life Sciences Announces Two Papers in the Journal Nucleic Acids Research Describing How PN Backbone Chemistry Modifications Enhance the Pharmacological Effects of Oligonucleotides

The Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) will support Wave Life Sciences Ltd's amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD) program.

Two Organizations To Support Wave Life Sciences' FTD, ALS Program

NEW YORK, Jan. 25, 2022 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) announced today that they have partnered to support Wave Life Sciences' FOCUS-C9 Phase 1b/2a clinical trial investigating WVE-004 as a potential treatment for C9orf72-associated frontotemporal degeneration (C9-FTD), as well as amyotrophic lateral sclerosis (C9-ALS). The partnership provides an investment from ADDF and AFTD that will support the evaluation of fluid biomarkers, functional assessments, and digital biomarkers in FOCUS-C9, potentially leading to clinically meaningful endpoints to inform development of treatments for FTD.

ADDF and AFTD Partner to Support Wave Life Sciences' FTD and ALS Clinical Program

Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q3 2021 Results - Earnings Call Transcript

Wave Life Sciences (WVE) delivered earnings and revenue surprises of 81.25% and 240.40%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Wave Life Sciences (WVE) Reports Q3 Loss, Tops Revenue Estimates

Strengthened balance sheet with approximately $52 million; focusing additional investment in RNA editing programs led by hepatic editing

Wave Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update

CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Stifel 2021 Virtual Healthcare Conference on Monday, November 15, 2021 at 10:00 a.m. ET.

Wave Life Sciences to Present at the Stifel 2021 Virtual Healthcare Conference

Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Wave Life Sciences (WVE) Report Negative Q3 Earnings? What You Should Know

CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, November 10, 2021, to discuss its third quarter 2021 financial results and provide a business update.

Wave Life Sciences to Webcast Conference Call of Third Quarter 2021 Financial Results on November 10, 2021

Takeda Pharmaceutical

Wave Life Sciences Ltd (NASDAQ: WVE) has amended its ongoing collaboration with Takeda Pharmaceutical Company Limited (NYSE: TAK) to discontinue discovery & research of preclinical programs for central nervous system (CNS) indications over a four-year research term. Under terms of the amendment, Takeda will pay Wave $22.5 million for collaboration-related research and preclinical expenses.

Wave Life Sciences, Takeda Discontinue Research On Preclinical CNS Programs

Amendment to ongoing collaboration allows Wave to advance or partner CNS programs, including those using ADAR editing

Wave Life Sciences and Takeda Amend CNS Collaboration

Wave Life Sciences Ltd (NASDAQ: WVE) presented new preclinical data for its ADAR-mediated RNA editing capability (ADAR editing) and an update on its discovery-stage alpha-1 antitrypsin deficiency (AATD) program.  Related Link: Wave Life Sciences' RNA Editing Platform Shows Restoration of Functional AAT Protein in Preclinical Study

Wave Life Sciences Shows Durable ADAR-Editing In Multiple Tissues In Animal Studies

Durable ADAR editing in vivo in preclinical models, including in CNS tissues with editing out to at least four months

Wave Life Sciences Announces New Data for Leading RNA Editing Capability Across Multiple Tissues and Provides Update on AATD Program During Analyst and Investor Research Webcast

CAMBRIDGE, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Chardan Virtual Genetic Medicines Conference on Monday, October 4, 2021 at 2:00 p.m. ET.

Wave Life Sciences to Present at the Chardan Virtual Genetic Medicines Conference

Live webcast scheduled for Tuesday, September 28, 2021 at 10:00 a.m. EDT Live webcast scheduled for Tuesday, September 28, 2021 at 10:00 a.m. EDT

Wave Life Sciences to Highlight RNA Editing Capability and AATD and Neurology Programs at 2021 Analyst and Investor Research Webcast on September 28, 2021

CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to give a pre-recorded presentation at the H.C. Wainwright 23rd Annual Global Investment Conference, which will be made available for on-demand viewing on Monday, September 13, 2021 at 7:00 a.m. ET.

News for Wave Life Sciences Stock (WVE)